800mg Abamune L Abacavir Sulphate Lamivudine Tablets

800mg Abamune L Abacavir Sulphate Lamivudine Tablets Specification

Indication
HIV-1 infection

Packaging Type
Box

Dosage Form
Tablet

Salt Composition
Abacavir (as sulphate) 600mg + Lamivudine 200mg

Brand Name
Abamune-L

Origin of Medicine
India

Life Span
24 Months

Pacakaging (Quantity Per Box)
30 Tablets

Drug Type
Allopathic

Ingredients
Abacavir Sulphate 600mg, Lamivudine 200mg

Physical Form
Tablets

Function
Antiretroviral (HIV treatment)

Recommended For
HIV positive adults and adolescents

Dosage
As directed by the physician

Dosage Guidelines
Take orally with or without food, as prescribed

Suitable For
Adults

Storage Instructions
Store at room temperature below 30C. Protect from light and moisture.

Prescription Required
Yes

Side Effects
May cause headache, nausea, fatigue, fever

Tablet Shape
Capsule-shaped

Marketed By
Cipla Ltd.

Regulatory Approval
WHO Prequalified

Warning
Not for use in children below 12 years or weighing less than 40kg

Therapeutic Class
Antiviral Agents

Administration Route
Oral

Manufactured By
Cipla Ltd.

Colour
Film-coated

800mg Abamune L Abacavir Sulphate Lamivudine Tablets Trade Information

Minimum Order Quantity
10 Pieces

Supply Ability
1000 Pieces Per Month

Delivery Time
7 Days

About 800mg Abamune L Abacavir Sulphate Lamivudine Tablets

Variant	Abamune-L
Manufacturer	Cipla
Packaging Type	Bottles
Packaging Size	30 Tablets
Brand	Abamune L
Treatment	Treat Human Immunodeficiency Virus (hiv) Infection
Composition	Abacavir Sulphate & Lamivudine

Abamune L 600 mg/300 mg Tablet is a combination of two anti-HIV medicines: Abacavir and Lamivudine. They prevent HIV (virus) from multiplying, thereby reducing the amount of virus in your body.

High-Efficacy Antiviral Combination

Abamune L integrates two potent antiretroviral agents-Abacavir Sulphate and Lamivudine-to effectively suppress the HIV-1 virus. This combination therapy slows virus replication, helps protect the immune system, and reduces the risk of developing drug resistance, making it a cornerstone in HIV management.

Designed for Adult HIV Treatment

Intended for adult patients and adolescents over 12 years or above 40kg, Abamune L is suitable for individuals diagnosed with HIV-1 infection. The recommended dosage is strictly as prescribed by a healthcare provider, ensuring tailored, safe, and optimal therapeutic outcomes.

Simple Oral Administration

With its capsule-shaped, film-coated design, Abamune L is easy to swallow and is administered orally. It may be taken with or without food, allowing flexibility and convenience. Instructions from the prescribing physician should always be followed to maximize effectiveness.

FAQ's of 800mg Abamune L Abacavir Sulphate Lamivudine Tablets:

Q: How should I take Abamune L 800mg Tablets?

A: Abamune L should be taken orally, once daily, with or without food, exactly as prescribed by your physician. Do not adjust your dose or discontinue use without medical advice.

Q: What conditions is Abamune L prescribed for?

A: Abamune L is indicated for the treatment of HIV-1 infection in adults and adolescents over 12 years or weighing more than 40kg. It is not suitable for children below these limits.

Q: When should I contact my doctor while using Abamune L?

A: Consult your physician if you experience side effects such as headache, nausea, fatigue, or fever, or if you miss a dose or notice any unusual symptoms during treatment.

Q: Where should I store Abamune L tablets?

A: Store Abamune L at room temperature below 30C in a dry place, away from light and moisture, to maintain its efficacy throughout its 24-month shelf life.

Q: What are the benefits of using Abamune L for HIV treatment?

A: Abamune L helps control HIV infection by reducing the viral load in the body, maintaining immune health, and lowering the risk of HIV-related complications when taken consistently as prescribed.

Q: What is the process for obtaining Abamune L?

A: Abamune L requires a valid prescription from a licensed healthcare provider and is supplied in packs of 30 tablets. It is manufactured and marketed by Cipla Ltd. in India and carries WHO prequalification.